SynthesisClinical and experimental medicine2025
Global and regional prevalence of osteopenia in chronic kidney disease: a systematic review and meta-analysis.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type 1 Diabetes Mellitus as a Model of Body Composition Transformation: Pathogenetic Unity of Combined Phenotypes.International journal of molecular sciences · 2026Review
- Combination of Biomarkers and Novel Diagnostic Tools in the Management of Osteoporosis in Chronic Kidney Disease: An Update.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of osteopenia among people with chronic kidney disease (CKD) remains uncertain. This research aimed to estimate the global and regional prevalence of osteopenia in CKD patients. Databases including PubMed, Scopus, Science Direct, Web of Science, and Embase, along with Google Scholar engine, were explored from January 1, 2000, to January 1, 2025, in English. The eligibility criteria included adults (≥ 18 years) with CKD stages 3a-5D. The risk of bias assessment performed using the Joanna Briggs Institute (JBI) checklist. The I-square index was employed to assess heterogeneity, whereas publication bias was evaluated through Egger's test and funnel plots. Statistical analyses were performed using Stata software Version 17. The prevalence of femoral neck osteopenia in CKDs estimated 47% (95% CI: 43 to 50, n = 45). The lumbar spine osteopenia estimated 35% (95% CI: 33 to 37, n = 52). Based on specific bone site, the osteopenia prevalence is 40% (95% CI: 35 to 45, n = 24) in total hip, 28% (95% CI: 19 to 38, n = 5) in forearm, and 31% (95% CI: 24 to 37, n = 9) in distal radius. The sex-specific rate is 37% (95% CI: 32 to 42, n = 30) for men and 36% (95% CI: 31 to 41, n = 30) for women. Our study uncovered a significant prevalence of osteopenia in CKD patients stages 3a-5D, with the highest rate in bone areas abundant in cortical content (femoral neck region).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.